Stories about: mechanobiology

The softer the nanoparticle, the better the drug delivery to tumors

Nanolipogels, pictured here, are a promising drug delivery system
Nanolipogels of different stiffness, as seen through a transmission electron microscope. Credit: Moses lab/Boston Children’s Hospital.

For the first time, scientists have shown that the elasticity of nanoparticles can affect how cells take them up in ways that can significantly improve drug delivery to tumors.

A team of Boston Children’s Hospital researchers led by Marsha A. Moses, PhD, who directs the Vascular Biology Program, created a novel nanolipogel-based drug delivery system that allowed the team to investigate the exclusive role of nanoparticle elasticity on the mechanisms of cell entry.

Their findings — that softer nanolipogels more efficiently enter cells using a different internalization pathway than their stiffer counterparts — were recently published in Nature Communications.

Read Full Story | Leave a Comment

The backstory behind organs-on-chips

Organs-on-chips drug testing drug discovery mechanobiology microfluidics Wyss Institute Vascular Biology Program
(Credit: Wyss Institute)

With the launch this summer of Emulate Inc., organs-on-chips—a disease-modeling platform we’ve covered several times on Vector—made the jump from academic to commercial development.

Though developed at the Wyss Institute for Biologically Inspired Engineering, the chips’ story actually began more than 20 years ago in Boston Children’s Hospital’s Vascular Biology Program (VBP). It’s a story that brings together characters from multiple fields and emerges from one fundamental concept: that mechanical forces are critical to the function and fate of cells, tissues and organs.

Read Full Story | Leave a Comment

Give me some skin (or not)

GROWTH CONTROL: Under conditions of low cell density (top image), Yap1, shown in green, is concentrated in cell nuclei, where it turns on growth-promoting genes. Under conditions of cell crowding (bottom image), Yap1 is kept out of cell nuclei (black areas) and is unable to act. Instead it's spread throughout the cell cytoplasm.

Generating new skin for burn victims and treating skin cancer are two sides of the same coin, according to a new study, which also reveals an inborn “crowd control” mechanism that flips the coin. Healthy people have a switch that senses how tightly cells are packed in the “neighborhood,” and turns growth-promoting genes on or off as needed in epidermal (skin-forming) stem cells.

Fernando Camargo, a researcher in the Children’s Hospital Boston Stem Cell Program, has worked out how this switch works and why it’s stuck “on” in cancers like squamous cell carcinoma, the second most common skin cancer. That could be a fresh clue to treating these cancers.

And as Camargo’s team demonstrated in mice, tinkering with that same switch could grow new skin when it’s needed, to heal a burn or ulcer.

Camargo, born in Peru and named a Pew Scholar last year at the age of 33, has been interested in understanding what maintains organs at a specific size. How do our skin and kidneys and livers “know” when it’s time to stop growing?

Read Full Story | 1 Comment | Leave a Comment